Shijiazhuang Huaxin Pharmaceutical Co., Ltd.

Main objective: To study the pharmacokinetics of aspirin enteric-coated tablets (specification: 0.1 g, licensed by Shijiazhuang Huaxin Pharmaceutical Co., Ltd.) and reference aspirin enteric-coated tablets (Bayaspirin®, specification: 0.1 g; licensed by Bayer S.p.A.) in healthy adult subjects after a single oral administration, and to evaluate the bioequivalence of the two oral preparations.

Primary objective: To investigate the in vivo pharmacokinetic characteristics of tolvaptan tablets (specification: 15 mg) produced by Shijiazhuang Huaxin Pharmaceutical Co., Ltd. and tolvaptan tablets (specification: 15 mg) produced by Zhejiang Otsuka Pharmaceutical Co., Ltd. through a bioequivalence study of oral administration of tolvaptan tablets, and to evaluate the bioequivalence of the two preparations. Secondary objective: To evaluate the safety of the test and reference preparations of single-dose oral tolvaptan tablets in healthy Chinese subjects.

Main purpose: Using pharmacokinetic parameters as the primary endpoint evaluation indicators, the pharmacokinetic behavior of the test preparation dapagliflozin tablets (manufacturer: Shijiazhuang Huaxin Pharmaceutical Co., Ltd.) and the reference preparation dapagliflozin tablets (licensed manufacturer: AstraZeneca AB, trade name: Andatang®) in healthy subjects after oral administration in the fasting/postprandial state was compared to evaluate the bioequivalence of the two preparations. Secondary purpose: Observe the safety of the test preparation dapagliflozin tablets and the reference preparation dapagliflozin tablets in healthy subjects.